Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (71-80 of 323) with videos related to

Pageof 33
Sort By:
Oncology|June 14, 2014
TP53 mutations in advanced colorectal cancer: the dark side of the moonFilippo Pietrantonio, Pamela Biondani, Federica Perrone, et al.
Cancers|September 27, 2014
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimensAntonia Martinetti, Rosalba Miceli, Elisa Sottotetti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 15, 2024
Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat StudyMarianna Maspero, Carlo Sposito, Marco A Bongini, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysisAlberto Giovanni Leone, Fausto Petrelli, Samuel J Klempner, et al.
European Journal of Cancer (Oxford, England : 1990)|February 13, 2015
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisFilippo Pietrantonio, Fausto Petrelli, Andrea Coinu, et al.
Critical Reviews in Oncology/Hematology|February 25, 2016
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, et al.
EMBO Molecular Medicine|July 20, 2018
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signalingCristina Migliore, Elena Morando, Elena Ghiso, et al.
Therapeutic Advances in Medical Oncology|November 16, 2020
Practical considerations in the use of regorafenib in metastatic colorectal cancerFotios Loupakis, Lorenzo Antonuzzo, Jean-Baptiste Bachet, et al.
International Journal of Cancer|February 24, 2015
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumabValeria Musella, Filippo Pietrantonio, Eleonora Di Buduo, et al.
European Radiology Experimental|August 26, 2024
Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation studyZuhir Bodalal, Eun Kyoung Hong, Stefano Trebeschi, et al.
Pageof 33

Showing results (71-80 of 323) with videos related to

Sort By:
Pageof 33
Oncology|June 14, 2014
TP53 mutations in advanced colorectal cancer: the dark side of the moonFilippo Pietrantonio, Pamela Biondani, Federica Perrone, et al.
Cancers|September 27, 2014
Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimensAntonia Martinetti, Rosalba Miceli, Elisa Sottotetti, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|November 15, 2024
Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat StudyMarianna Maspero, Carlo Sposito, Marco A Bongini, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2025
Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysisAlberto Giovanni Leone, Fausto Petrelli, Samuel J Klempner, et al.
European Journal of Cancer (Oxford, England : 1990)|February 13, 2015
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysisFilippo Pietrantonio, Fausto Petrelli, Andrea Coinu, et al.
Critical Reviews in Oncology/Hematology|February 25, 2016
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, et al.
EMBO Molecular Medicine|July 20, 2018
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signalingCristina Migliore, Elena Morando, Elena Ghiso, et al.
Therapeutic Advances in Medical Oncology|November 16, 2020
Practical considerations in the use of regorafenib in metastatic colorectal cancerFotios Loupakis, Lorenzo Antonuzzo, Jean-Baptiste Bachet, et al.
International Journal of Cancer|February 24, 2015
Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumabValeria Musella, Filippo Pietrantonio, Eleonora Di Buduo, et al.
European Radiology Experimental|August 26, 2024
Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation studyZuhir Bodalal, Eun Kyoung Hong, Stefano Trebeschi, et al.
Pageof 33